Skip to main content
Top
Published in: European Journal of Epidemiology 2/2015

Open Access 01-02-2015 | META-ANALYSIS

Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis

Authors: Esther Jane Aspinall, Joseph Samuel Doyle, Stephen Corson, Margaret Elena Hellard, David Hunt, David Goldberg, Tim Nguyen, Yngve Falck-Ytter, Rebecca Lynn Morgan, Bryce Smith, Mark Stoove, Stefan Zbyszko Wiktor, Sharon Hutchinson

Published in: European Journal of Epidemiology | Issue 2/2015

Login to get access

Abstract

Testing for hepatitis C virus (HCV) infection may reduce the risk of liver-related morbidity, by facilitating earlier access to treatment and care. This review investigated the effectiveness of targeted testing interventions on HCV case detection, treatment uptake, and prevention of liver-related morbidity. A literature search identified studies published up to 2013 that compared a targeted HCV testing intervention (targeting individuals or groups at increased risk of HCV) with no targeted intervention, and results were synthesised using meta-analysis. Exposure to a targeted testing intervention, compared to no targeted intervention, was associated with increased cases detected [number of studies (n) = 14; pooled relative risk (RR) 1.7, 95 % CI 1.3, 2.2] and patients commencing therapy (n = 4; RR 3.3, 95 % CI 1.1, 10.0). Practitioner-based interventions increased test uptake and cases detected (n = 12; RR 3.5, 95 % CI 2.5, 4.8; and n = 10; RR 2.2, 95 % CI 1.4, 3.5, respectively), whereas media/information-based interventions were less effective (n = 4; RR 1.5, 95 % CI 0.7, 3.0; and n = 4; RR 1.3, 95 % CI 1.0, 1.6, respectively). This meta-analysis provides for the first time a quantitative assessment of targeted HCV testing interventions, demonstrating that these strategies were effective in diagnosing cases and increasing treatment uptake. Strategies involving practitioner-based interventions yielded the most favourable outcomes. It is recommended that testing should be targeted at and offered to individuals who are part of a population with high HCV prevalence, or who have a history of HCV risk behaviour.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRef Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRef
3.
go back to reference Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540–50.CrossRefPubMedCentralPubMed Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540–50.CrossRefPubMedCentralPubMed
4.
go back to reference Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141–7.CrossRefPubMed Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141–7.CrossRefPubMed
5.
go back to reference Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.CrossRefPubMedCentralPubMed Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.CrossRefPubMedCentralPubMed
6.
go back to reference Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. J Am Med Assoc. 1990;264:2231–5.CrossRef Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. J Am Med Assoc. 1990;264:2231–5.CrossRef
7.
go back to reference Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274–7.PubMedCentralPubMed Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274–7.PubMedCentralPubMed
8.
go back to reference Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21:983–91.CrossRefPubMed Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21:983–91.CrossRefPubMed
9.
go back to reference Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880–9.CrossRefPubMed Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880–9.CrossRefPubMed
10.
go back to reference Karmochine M, Carrat F, Dos Santos O, Cacoub P, Raguin G, for the GERMIVIC Study Group. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat. 2006;13:775–82.CrossRef Karmochine M, Carrat F, Dos Santos O, Cacoub P, Raguin G, for the GERMIVIC Study Group. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat. 2006;13:775–82.CrossRef
11.
go back to reference Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331–9.CrossRefPubMed Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331–9.CrossRefPubMed
12.
go back to reference Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRefPubMed Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRefPubMed
14.
go back to reference European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRef European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRef
15.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB, on behalf of the American Association for the Study of Liver Diseases (AASLD). AASLD practice guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB, on behalf of the American Association for the Study of Liver Diseases (AASLD). AASLD practice guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed
16.
go back to reference Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis MA. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review. Eur J Public Health. 2013;. doi:10.1093/eurpub/ckt156.PubMedCentral Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis MA. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review. Eur J Public Health. 2013;. doi:10.​1093/​eurpub/​ckt156.PubMedCentral
19.
go back to reference Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, on behalf of the GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.CrossRefPubMedCentralPubMed Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, on behalf of the GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.CrossRefPubMedCentralPubMed
20.
go back to reference Blanchet E, Defossez G, Verneau A, Ingrand I, Silvain C, Beauchant M. Epidemiology and management of care of hepatitis C infection in the Poitou–Charentes region in 1997 and 2000. Gastroenterol Clin Biol. 2003;27:1026–30.PubMed Blanchet E, Defossez G, Verneau A, Ingrand I, Silvain C, Beauchant M. Epidemiology and management of care of hepatitis C infection in the Poitou–Charentes region in 1997 and 2000. Gastroenterol Clin Biol. 2003;27:1026–30.PubMed
21.
go back to reference Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou–Charentes region. Eur J Gastroenterol Hepatol. 2008;20:367–72.CrossRefPubMed Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou–Charentes region. Eur J Gastroenterol Hepatol. 2008;20:367–72.CrossRefPubMed
22.
go back to reference Helsper CW, Borkent-Raven BA, De Wit NJ, Van Essen GA, Bonten MJM, Hoepelman AIM, et al. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. Epidemiol Infect. 2012;140:58–69.CrossRefPubMed Helsper CW, Borkent-Raven BA, De Wit NJ, Van Essen GA, Bonten MJM, Hoepelman AIM, et al. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. Epidemiol Infect. 2012;140:58–69.CrossRefPubMed
23.
go back to reference Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012;44:497–503.CrossRefPubMed Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012;44:497–503.CrossRefPubMed
24.
go back to reference Sahajian F, Bailly F, Vanhems P, Fantino B, Vannier-Nitenberg C, Fabry J, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health. 2011;33:182–92.CrossRef Sahajian F, Bailly F, Vanhems P, Fantino B, Vannier-Nitenberg C, Fabry J, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health. 2011;33:182–92.CrossRef
25.
go back to reference Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines’ implementation. Br J Gen Pract. 2006;56:848–56.PubMedCentralPubMed Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines’ implementation. Br J Gen Pract. 2006;56:848–56.PubMedCentralPubMed
26.
go back to reference Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15:250–4.CrossRefPubMed Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15:250–4.CrossRefPubMed
27.
go back to reference Roudot-Thoraval F, Monnet E, Mercet P, Bastie A, Dhumeaux D, Miguet JP. Strategies of hepatitis C screening in general practice. Results of a two-center randomized trial. Gastroenterol Clin Biol. 2000;24:1037–41.PubMed Roudot-Thoraval F, Monnet E, Mercet P, Bastie A, Dhumeaux D, Miguet JP. Strategies of hepatitis C screening in general practice. Results of a two-center randomized trial. Gastroenterol Clin Biol. 2000;24:1037–41.PubMed
28.
go back to reference Anderson EM, Mandeville RP, Hutchinson SJ, Cameron SO, Mills PR, Fox R, et al. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J. 2009;54:3–7.CrossRefPubMed Anderson EM, Mandeville RP, Hutchinson SJ, Cameron SO, Mills PR, Fox R, et al. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J. 2009;54:3–7.CrossRefPubMed
29.
go back to reference Cullen BL, Hutchinson SJ, Cameron SO, Anderson E, Ahmed S, Spence E, et al. Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health. 2012;34:14–23.CrossRef Cullen BL, Hutchinson SJ, Cameron SO, Anderson E, Ahmed S, Spence E, et al. Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health. 2012;34:14–23.CrossRef
30.
go back to reference Helsper CW, van Essen GA, Bonten MJM, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010;27:328–32.CrossRefPubMed Helsper CW, van Essen GA, Bonten MJM, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010;27:328–32.CrossRefPubMed
31.
go back to reference Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G. What is the best method of case finding for chronic viral hepatitis in at-risk migrant communities? J Hepatol. 2012;56:S351.CrossRef Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G. What is the best method of case finding for chronic viral hepatitis in at-risk migrant communities? J Hepatol. 2012;56:S351.CrossRef
32.
go back to reference Lacey C, Ellen S, Devlin H, Wright E, Mijch A. Hepatitis C in psychiatry inpatients: testing rates, prevalence and risk behaviours. Australas Psychiatry. 2007;15:315–9.CrossRefPubMed Lacey C, Ellen S, Devlin H, Wright E, Mijch A. Hepatitis C in psychiatry inpatients: testing rates, prevalence and risk behaviours. Australas Psychiatry. 2007;15:315–9.CrossRefPubMed
33.
go back to reference Sahajian F, Excler G, Bailly F, Caillat-Vallet E, Trepo C, Sepetjan M, et al. Hepatitis C screening practices among private practitioners: impact of an information campaign. Gastroenterol Clin Biol. 2004;28:714–9.CrossRefPubMed Sahajian F, Excler G, Bailly F, Caillat-Vallet E, Trepo C, Sepetjan M, et al. Hepatitis C screening practices among private practitioners: impact of an information campaign. Gastroenterol Clin Biol. 2004;28:714–9.CrossRefPubMed
34.
go back to reference Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:447–51.PubMedCentralPubMed Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:447–51.PubMedCentralPubMed
35.
go back to reference Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the US preventive services task force. Ann Intern Med. 2013;158:101–8.CrossRefPubMed Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the US preventive services task force. Ann Intern Med. 2013;158:101–8.CrossRefPubMed
36.
go back to reference Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Hepatitis C clinical database monitoring committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547–58.CrossRefPubMed Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Hepatitis C clinical database monitoring committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547–58.CrossRefPubMed
37.
go back to reference Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8.CrossRefPubMed Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8.CrossRefPubMed
39.
go back to reference Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10:32.CrossRef Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10:32.CrossRef
40.
go back to reference Rein DB, Smith BS, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263–70.CrossRefPubMed Rein DB, Smith BS, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263–70.CrossRefPubMed
41.
go back to reference Kennedy CE, Fonner VA, Sweat MD, AmoloOkero F, Baggaley R, O’Reilly KR. Provider-initiated HIV testing and counselling in low- and middle-income countries: a systematic review. AIDS Behav. 2013;17:1571–90.CrossRefPubMedCentralPubMed Kennedy CE, Fonner VA, Sweat MD, AmoloOkero F, Baggaley R, O’Reilly KR. Provider-initiated HIV testing and counselling in low- and middle-income countries: a systematic review. AIDS Behav. 2013;17:1571–90.CrossRefPubMedCentralPubMed
Metadata
Title
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis
Authors
Esther Jane Aspinall
Joseph Samuel Doyle
Stephen Corson
Margaret Elena Hellard
David Hunt
David Goldberg
Tim Nguyen
Yngve Falck-Ytter
Rebecca Lynn Morgan
Bryce Smith
Mark Stoove
Stefan Zbyszko Wiktor
Sharon Hutchinson
Publication date
01-02-2015
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 2/2015
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-014-9958-4

Other articles of this Issue 2/2015

European Journal of Epidemiology 2/2015 Go to the issue